Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7 Polycystic Ovary Syndrome 2 Neoplasms 2 Urinary Bladder Neoplasms 1 Stage I Prostate Adenocarcinoma 1 Prostatic Neoplasms 1 Osteoporosis 1 Infertility 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Diarrhea 1 Cardiovascular Diseases 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Anovulation 1 Adenocarcinoma 1

Interventions

Octreotide 6 Irinotecan 6 Loperamide 5 Probiotics 3 Leucovorin 3 Fluorouracil 3 Fecal Microbiota Transplantation 3 Calcium Aluminosilicate 3 maltodextrin 2 telotristat ethyl 1 shosaiko-to 1 lanreotide 1 isatuximab 1 ceterizine hydrochloride 1 capivasertib 1 cabazitaxel 1 bile acid binding proteins 1 XRP6258 1 Theophylline 1 Temozolomide 1 Surveys and Questionnaires 1 Sulfasalazine 1 Sugars 1 Standard of Care 1 Raloxifene Hydrochloride 1 Radiation 1 Prednisone 1 PHY 906 1 Oxaliplatin 1 Long-Term Synaptic Depression 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Diarrhea × Raloxifene Hydrochloride × Clear all

NCT04926545 2024-07-30

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Guangzhou University of Traditional Chinese Medicine

Phase NA Completed

Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡